Differentiation therapy in poor risk myeloid malignancies: results of a dose finding study of the combination bryostatin-1 and GM-CSF
BD Smith, RJ Jones, E Cho, J Kowalski, JE Karp… - Leukemia research, 2011 - Elsevier
PURPOSE: Pharmacologic differentiating agents have had relatively limited clinical success
outside of the use of ATRA in acute promyelocytic leukemia and DNA methyltransferase
inhibitors in myelodysplastic syndromes. The differentiating effects of such agents can be
enhanced in combination with lineage-specific growth factors. We developed a dose finding
trial to assess toxicity, differentiating activity, and clinical impact of the combination of
bryostatin-1 and GM-CSF. EXPERIMENTAL DESIGN: Patients with poor risk myeloid …
outside of the use of ATRA in acute promyelocytic leukemia and DNA methyltransferase
inhibitors in myelodysplastic syndromes. The differentiating effects of such agents can be
enhanced in combination with lineage-specific growth factors. We developed a dose finding
trial to assess toxicity, differentiating activity, and clinical impact of the combination of
bryostatin-1 and GM-CSF. EXPERIMENTAL DESIGN: Patients with poor risk myeloid …